Bendamustine anionic-catioinic cyclopolysaccharide compositions
The present invention is directed to pharmaceutical compositions including: (a) bendamustine, (b) a first charged cyclopolysaccharide, and (c) a stabilizing agent which is a second charged cyclopolysaccharide having a charge opposite to that of the first charged cyclopolysaccharide. The composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. The compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.
1. A composition comprising:
(a) bendamustine;
(b) a first charged cyclopolysaccharide selected from the group consisting of sulfobutyl ether beta-cyclodextrin, sodium sulfopropylated-beta-cyclodextrin, and sodium O-sulfated-beta-cyclodextrin; and
(c) a stabilizing agent which is a second charged cyclopolysaccharide selected from the group consisting of heptakis(6-amino-6-deoxy) beta-cyclodextrin, heptakis(6-guanidino-6-deoxy) beta-cyclodextrin, and 6-deoxy-6-(3-hydroxy)propylamino beta-cyclodextrin.
2. The composition of claim 1 wherein component (b) is sulfobutyl ether beta-cyclodextrin.
3. The composition of claim 1 wherein component (c) is heptakis(6-amino-6-deoxy) beta-cyclodextrin.
4. The composition of claim 1 wherein the bendamustine is in the form of bendamustine hydrochloride.
5. A composition comprising:
(a) bendamustine;
(b) a first charged cyclopolysaccharide, said first charged cyclopolysaccharide is sulfobutyl ether beta-cyclodextrin; and
(c) a stabilizing agent which is a second charged cyclopolysaccharide having a charge opposite to that of the first charged cyclopolysaccharide, said stabilizing agent is heptakis(6-amino-6-deoxy) beta-cyclodextrin.
6. The composition of claim 5 wherein the bendamustine is in the form of bendamustine hydrochloride.